Status:
RECRUITING
Shared Decision Making in Patients With Lung Cancer
Lead Sponsor:
Sichuan Cancer Hospital and Research Institute
Collaborating Sponsors:
Jiangyou People's Hospital
Wu Jieping Medical Foundation
Conditions:
Surgery
Lung Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to develop a Decision Aid for Lung Cancer Molecular Testing (DA\_LCMT) and to facilitate shared-decision making in patients who were diagnosed with lung adenocarcinoma b...
Detailed Description
Under the guidance by Ottawa Decision Support Framework (ODSF), International Patient Decision Aid Standards (IPDAS) and FDA guidance for Identify what is important to patients, the investigators use ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients of decision-making need assessment:
- 1\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have or have not made a decision on lung cancer molecular testing (whether to perform molecular testing or not).
- Other stakeholders of decision-making need assessment:
- 1\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process.
- Patients of Cognitive debriefing/Alpha tests:
- 1\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have made a decision on whether to perform lung cancer molecular testing or not.
- other stakeholders of Cognitive debriefing/Alpha tests:
- 1\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process.
- Patients of field testing /Beta tests:
- 1\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have not decided whether to perform lung cancer molecular testing or not.
- Clinician of field testing /Beta tests:
- 1\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; and 4) voluntarily participated in this study.
- Exclusion criteria:
- Inability to understand the research content.
Exclusion
Key Trial Info
Start Date :
February 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT05191485
Start Date
February 22 2023
End Date
December 1 2026
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sichuan Cancer Hospital & Institute
Chengdu, Sichuan, China, 610041